Karlsruhe Institute of Technology, which spun out Amcure in 2012, has participated in a round led by LBBW Venture Capital.

Washington Research Foundation and Arch Venture Partners are among the investors in the genomic cancer treatment spinout of University of Minnesota.

AbbVie, Eli Lilly, WuXi PharmaTech, Johnson & Johnson and Alexandria Real Estate Equities are among the investors in the genomic cancer treatment developer.

Henry Crown and Company and Dinova Capital joined existing shareholders in a $35m funding round for dentistry product developer Sonendo.

Bayer Lifescience Center joined Versant Ventures to launch BlueRock, a Kyoto spinout that will develop stem cell treatments for cardiovascular diseases and neurodegenerative disorders.

Bill Maris, managing partner of GV until August, has dropped plans for a healthcare fund despite having access to available capital, he has revealed.

The Illumina-backed company has raised additional funding after becoming the first company to sequence multiple human genomes using portable technology.

Bayer Lifescience Center joined Versant Ventures to launch BlueRock, which will develop stem cell treatments for cardiovascular diseases and neurodegenerative disorders.

The biotherapeutics developer, a UCSF spinout, raised funds from backers like cancer immunotherapy developer Kite Pharma, a UCLA spinout.